Warning to ophthalmologists

Article

"When treating patients with DME, ophthalmologists should consider the role of the glitazone class of drugs," warn the authors of a study published in the April issue of the American Journal of Ophthalmology.

"When treating patients with DME, ophthalmologists should consider the role of the glitazone class of drugs," warn the authors of a study published in the April issue of the American Journal of Ophthalmology.

Whilst the diabetes drug class, glitazones has been associated with an increased risk of diabetic macular oedema (DME) in the past, this piece of research confirms that the drugs, which include pioglitazone (Actos) and rosiglitazone (Avandia) are 'modestly associated' with increased DME.

Recent Videos
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
Carl J. Danzig, MD
Martin Zinkernagel, MD, PhD, speaks about the ASRS sustainability expert panel
Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal GA
© 2024 MJH Life Sciences

All rights reserved.